Special Report: 2013-14 PBS

Growth in spending on the PBS remained at historically low levels, what growth there is has been driven by specialist and hospital medicines, the scheme's 'Top 10' drugs in terms of Government spending has undergone a price disclosure driven transformation, the under co-payment category is growing quickly, and generic companies have been the big winners in terms of volume but not necessarily value, recording dramatic increases in market share. …